Officer Files Intent to Sell $51.5M in Stock Following $600M Public Offering
TNGX has more than doubled off its 52-week low of $4.322 on elevated volume (1.8× avg).
Summary
An officer at Tango Therapeutics has filed to sell over $51 million in stock, a substantial amount, just after the company completed a $600 million public offering.
Key Events · Ownership and Investor Activity · TNGX
-
Officer Files Intent to Sell Significant Stake
Daniella Beckman, an officer, filed a Form 144 to sell 1,791,726 shares of common stock, valued at approximately $51.5 million.
-
Sale Follows Major Capital Raise
This proposed sale occurs immediately after the company priced an upsized $600 million public offering at $30.00 per share on June 10, 2026.
-
Shares Acquired Through Vesting
The shares intended for sale were acquired through stock option exercise and vesting of restricted stock.
Analysis · TNGX · Life Sciences
Daniella Beckman, an officer at Tango Therapeutics, has filed a Form 144 indicating intent to sell 1,791,726 shares of common stock, valued at approximately $51.5 million. This significant proposed sale, representing about 1.2% of the company's market capitalization, comes immediately after Tango Therapeutics completed an upsized $600 million public offering. While the shares were acquired through stock option exercise and restricted stock vesting, the timing and magnitude of this sale could be interpreted negatively by investors, especially given the recent capital raise.
At the time of this filing, TNGX was trading at $29.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $4.32 to $32.79. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.